pharmaphorum
JANUARY 5, 2022
The next phase of the Covid-19 – from vaccines to treatments. This response is at a speed that would be considered unthinkable pre-pandemic, but, given a highly transmissible variant and the ever-present threat of new variants of concern, it may still not be fast enough. This may pose a barrier to effective use.
BuzzRx
NOVEMBER 18, 2022
Please continue reading to learn about some of the most effective treatments for folliculitis. If you have certain health conditions or are taking medications that weaken the immune system, treatment is almost always warranted, as your body cannot clear infections well enough compared to others. What is folliculitis?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BuzzRx
FEBRUARY 6, 2023
Eccrine glands are present all over the body, including the palms and soles. Apocrine glands open into the hair follicles and are present in the groin and underarms. However, there is no evidence of a lasting improvement in excessive sweating with these treatments. They secrete sweat that evaporates and has a cooling effect.
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. Launch opportunity is reduced.
Druggist
SEPTEMBER 2, 2021
Experts believe that this medicine can be highly effective against parasites present inside and outside the body. Additionally, this drug is also known as anti-parasite successful against all viruses like HIV, Dengue, Influenza , and Zika virus. And stated its judicial use in preventing corona infection. So, we’ve learned that.
PharmaShots
APRIL 25, 2023
This year Roche has secured the top position with a total R&D Expenditure of $15.20B, followed by Johnson & Johnson and AstraZeneca PharmaShots presents the Top 20 RNAi therapeutic companies based on their R&D Expenditure in the year 2022 R&D Expenditure: $43.1M R&D Expenditure: $85.1M R&D Expenditure: $437.9M
ISPE
JULY 6, 2023
1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Operational Flexibility/Capacity Decentralized manufacturing Presently, portable end-to-end CM plants are not a widespread reality, but have been proven possible.
Expert insights. Personalized for you.
95 
Let's personalize your content